Shashwat Sharma to be Airtel MD & CEO from January 1, 2026

Bharti Airtel on Monday announced the appointment of Shashwat Sharma as the new managing director and chief executive officer (CEO) of the company effective January 1, 2026. Sharma, who is currently the chief operation officer (COO), will replace Gopal Vittal, who is being appointed as the executive vice chairman of Bharti Airtel.

“As the CEO designate, Shashwat will be responsible for the entire end-to-end consumer business. Gopal will be responsible for mentoring and grooming Shashwat to take over as MD & CEO of Bharti Airtel,” the company said in an exchange filing.

Also ReadSpecial Diwali offer for Indians! Ubuy announces free international shipping on Nov 1-3

Currently, as part of a structured succession process,Vittal, in addition to being the managing director, is also being appointed as vice chairman of Bharti Airtel. In this role, while continuing to lead the India business, he will take on broader telecom responsibilities across the group. Vittal will be appointed to the Board of Airtel Africa Plc as the Bharti nominee director to provide strategic guidance. In addition, he will be responsible for driving group synergies in select areas such as network strategy, digital & technology, procurement and talent. On January 1, 2026, Vittal will move into the role of executive vice chairman of Bharti Airtel.

Also Read Vijaya Kishore Rahatkar appointed as National Commission for Women’s ninth chairperson SAT adjourns Reliance Commercial Finance & Pinkesh Shah’s pleas to October 22 NSE yet to take a call on single weekly index as directed by SEBI, says Ashish Chauhan Govt eyes place for ‘Made in India’ brand on global stage

Vittal has served Bharti Airtel as MD & CEO for the last twelve years. In this period, Airtel has built a winning portfolio of businesses across mobile, B2B (business to business), home broadband, direct to home (DTH), and digital services.

In mobile, Airtel has seen its revenue market share grow from 30% to 40%, with Vittal leading the company. Infact, Airtel also recently witnessed its market capitalisation of over $100 billion.

Sunil Bharti Mittal, chairman of Bharti Airtel, said, “India’s foremost corporate entity, has had a distinguished record of well thought out structured succession planning. I am extremely pleased with the succession and transition plan of leadership at Airtel and there could not have been a better time for Airtel to unveil the new arrangement where change and continuity will go hand in hand”.

 » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth